2019
DOI: 10.1159/000499540
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Inflammation is substantially contributing to the development and worsening of diabetic retinopathy in general and diabetic macular edema (DME) in particular, which provides the rationale to treat DME with corticosteroids. While anti-vascular endothelial growth factor (VEGF) agents are mostly chosen as a first-line treatment, there is an important role for steroids in the treatment algorithm for DME. A slow-release bioerodible dexamethasone implant and an extended-release nonbioerodible fluocinolone acetonide … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
58
2

Year Published

2019
2019
2023
2023

Publication Types

Select...
5
3
2

Relationship

0
10

Authors

Journals

citations
Cited by 87 publications
(60 citation statements)
references
References 55 publications
0
58
2
Order By: Relevance
“…Recently, a large GWAS highlighted new genes and pathways involved in the development of AMD, including complement activation, collagen synthesis, lipid metabolism/cholesterol transport, receptor-mediated endocytosis, endodermal cell differentiation, and extracellular matrix organization, indicating that many unknown genetic changes remain to be identified with respect to the initiation and development of AMD [20]. The application of novel drugs in the treatment of macular disease also indicated the complicated change of the micro-environment of the macular in the case of disease [29][30][31]. In this study, we screened novel biomarkers by combining microarray information from RPE-choroid and retinal tissue samples from patients with AMD, as well as peripheral blood samples, by overlapping relevant datasets (GSE29801 and GSE10295) using integrated bioinformatics analysis for available microarray data.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, a large GWAS highlighted new genes and pathways involved in the development of AMD, including complement activation, collagen synthesis, lipid metabolism/cholesterol transport, receptor-mediated endocytosis, endodermal cell differentiation, and extracellular matrix organization, indicating that many unknown genetic changes remain to be identified with respect to the initiation and development of AMD [20]. The application of novel drugs in the treatment of macular disease also indicated the complicated change of the micro-environment of the macular in the case of disease [29][30][31]. In this study, we screened novel biomarkers by combining microarray information from RPE-choroid and retinal tissue samples from patients with AMD, as well as peripheral blood samples, by overlapping relevant datasets (GSE29801 and GSE10295) using integrated bioinformatics analysis for available microarray data.…”
Section: Discussionmentioning
confidence: 99%
“…The application of novel drugs in the treatment of macular disease also indicated the complicated change of the micro-environment of the macular in the case of disease [29][30][31]. In this study, we screened novel biomarkers by combining microarray information from RPE-choroid and retinal tissue samples from patients with AMD, as well as peripheral blood samples, by overlapping relevant datasets (GSE29801 and GSE10295) using integrated bioinformatics analysis for available microarray data.…”
Section: Discussionmentioning
confidence: 99%
“…Corticosteroids reduce not only leukostasis and inflammatory cytokine production, but also VEGF expression [19]. Several studies have indicated that steroids were effective and safe for diabetic macular edema (DME) eyes' treatment [20][21][22][23][24][25].…”
Section: Introductionmentioning
confidence: 99%